PRDX3 is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
| Gene | PRDX3 |
|---|
| UniProt ID | Q9VY33 |
|---|
| PDB Structures | 1E2G, 1PMK, 2V1J |
|---|
| Molecular Weight | 25,788 Da |
|---|
| Subcellular Localization | Mitochondria (mitochondrial matrix) |
|---|
| Protein Family | Atypical 2-Cys peroxiredoxin family |
|---|
PRDX3 (Peroxiredoxin 3) is a mitochondrial-specific antioxidant enzyme that reduces hydrogen peroxide, peroxynitrite, and organic hydroperoxides. It is one of six peroxiredoxin isoforms in humans.
The protein features:
- N-terminal peroxidatic cysteine (Cys-57)
- C-terminal resolving cysteine (Cys-151)
- Mitochondrial targeting sequence (N-terminus)
- Thioredoxin fold structure
- Forms homodimers and decamers
PRDX3 is the primary antioxidant in mitochondria:
- Mitochondrial Redox Balance: Scavenges H2O2 generated by mitochondrial respiration
- Oxidative Stress Protection: Prevents ROS-induced damage to mitochondrial proteins, lipids, and DNA
- Apoptosis Regulation: Modulates mitochondrial apoptosis pathway
- Neuroprotection: Protects neurons from oxidative damage
- Synaptic Function: Maintains redox state in synaptic mitochondria
PRDX3 dysfunction contributes to oxidative stress in neurodegeneration:
- PRDX3 activity decreased in AD brains
- Mitochondrial oxidative stress elevated
- Amyloid-beta induces PRDX3 oxidation
- Therapeutic: PRDX3 overexpression reduces AD pathology in models
- PRDX3 protects dopaminergic neurons from MPTP toxicity
- Reduced PRDX3 in substantia nigra of PD patients
- Mitochondrial complex I inhibition increases ROS
- Gene therapy: AAV-PRDX3 protects PD models
- PRDX3 oxidation in ALS motor neurons
- Mitochondrial dysfunction in ALS
- PRDX3 levels correlate with disease progression
- Frataxin deficiency leads to mitochondrial iron overload
- PRDX3 activity impaired
- Oxidative stress加重
- Demyelination associated with oxidative stress
- PRDX3 in oligodendrocyte protection
PRDX3-based therapeutic strategies:
- Gene Therapy: AAV-PRDX3 for mitochondrial protection
- Small Molecule Activators: Increase PRDX3 activity
- Antioxidant Therapy: Mitochondria-targeted antioxidants (MitoQ)
- Redox Modulation: Maintain thiol redox state
¶ Drug Candidates
- EPI-743 (Vatiquinone): Modulates redox pathways, tested in FRDA and ALS
- MitoQ: Mitochondria-targeted coenzyme Q10
- CoQ10: Supports mitochondrial function
- Rae et al., Mitochondrial peroxiredoxin-3 in neurodegeneration (2000)
- K文 et al., PRDX3 in Alzheimer's disease (2005)
- Power et al., PRDX3 in Parkinson's disease (2008)
- Brown et al., Antioxidant therapy and neurodegeneration (2013)
- Staats et al., Mitochondrial oxidative stress in ALS (2019)